Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA – Get Free Report) CAO Michael R. Megna sold 9,051 shares of the business’s stock in a transaction on Wednesday, March 12th. The stock was sold at an average price of $22.45, for a total value of $203,194.95. Following the completion of the sale, the chief accounting officer now directly owns 26,528 shares in the company, valued at $595,553.60. This represents a 25.44 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this link.
Kiniksa Pharmaceuticals Trading Up 2.0 %
Shares of KNSA stock opened at $22.61 on Friday. Kiniksa Pharmaceuticals, Ltd. has a 1-year low of $16.56 and a 1-year high of $28.15. The company has a market capitalization of $1.64 billion, a price-to-earnings ratio of -161.49 and a beta of 0.48. The stock’s fifty day simple moving average is $19.95 and its 200-day simple moving average is $22.22.
Kiniksa Pharmaceuticals (NASDAQ:KNSA – Get Free Report) last issued its quarterly earnings results on Tuesday, February 25th. The company reported ($0.12) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.06) by ($0.06). Kiniksa Pharmaceuticals had a negative net margin of 2.36% and a negative return on equity of 7.31%. The business had revenue of $122.50 million for the quarter, compared to analysts’ expectations of $123.42 million. During the same quarter in the prior year, the firm posted $0.35 EPS. The business’s quarterly revenue was up 46.9% compared to the same quarter last year. On average, sell-side analysts predict that Kiniksa Pharmaceuticals, Ltd. will post -0.55 EPS for the current year.
Institutional Inflows and Outflows
Wall Street Analyst Weigh In
A number of analysts have recently commented on KNSA shares. Citigroup initiated coverage on Kiniksa Pharmaceuticals in a research note on Thursday. They issued a “buy” rating and a $40.00 price objective on the stock. Wedbush restated an “outperform” rating and issued a $34.00 target price on shares of Kiniksa Pharmaceuticals in a report on Tuesday, February 25th. Six equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Kiniksa Pharmaceuticals presently has a consensus rating of “Buy” and an average price target of $37.17.
About Kiniksa Pharmaceuticals
Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.
Recommended Stories
- Five stocks we like better than Kiniksa Pharmaceuticals
- What Are Earnings Reports?
- MarketBeat Week in Review – 03/10 – 03/14
- How to Use High Beta Stocks to Maximize Your Investing Profits
- Rubrik Stock’s V-Bottom Reversal Signals a Major Rally Ahead
- Bank Stocks – Best Bank Stocks to Invest In
- How Super Micro Computer Stock Is Defying the Market Sell-Off
Receive News & Ratings for Kiniksa Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kiniksa Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.